依奇珠單抗

依奇珠單抗
單克隆抗體
種類	完整抗體
目標	介白素17A（英語：Interleukin 17A） (IL-17A)
臨床資料
讀音	ix-ee-KIZ-ue-mab
商品名（英語：Drug nomenclature）	Taltz
AHFS/Drugs.com	Monograph
MedlinePlus	a616025
核准狀況	美 DailyMed: Ixekizumab;
懷孕分級	澳: C ; ;
給藥途徑	皮下注射
ATC碼	L04AC13 (WHO) ;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 加：處方藥（℞-only）; 歐：Rx-only; 英：處方藥（℞-only） (POM); 美：處方藥（℞-only）; 處方藥（℞-only）;
藥物動力學數據
生物利用度	60–81%
藥物代謝	大概是蛋白酶解
生物半衰期	13天
識別資訊
CAS號	1143503-69-8
DrugBank	DB11569 ;
ChemSpider	none;
UNII	BTY153760O;
KEGG	D10071;
ChEMBL	ChEMBL1743034;
化學資訊
化學式	C6492H10012N1728O2028S46
摩爾質量	146,192.34 g·mol−1

依奇珠單抗（英語：Ixekizumab），商品名達癬治（英語：Taltz），是治療斑塊狀乾癬、乾癬性關節炎和僵直性脊椎炎的皮下注射藥物^[10] ^[11]。對斑塊狀銀屑病，適用於中度至重度疾病^[10]。

常見副作用包括呼吸道感染和注射部位疼痛^[10]。其他副作用包括可能感染和過敏^[11]。不建議於孕期使用，因安全性不明^[12]。它是單克隆抗體，結合併阻斷介白素17A（英語：Interleukin-17A），並減輕發炎^[10]。

依奇珠單抗於2016年在歐洲和美國取得醫療使用許可^[11] ^[10]。

參考文獻

^ 12 Difficult-to-Pronounce Drug Names. Pharmacy Times. 7 February 2018 [22 March 2018]. （原始內容存檔於21 March 2018）.
^ Ixekizumab (Taltz) Use During Pregnancy. Drugs.com. 27 November 2019 [27 March 2020].
^ Prescription medicines: registration of new chemical entities in Australia, 2016. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].
^ Health Canada New Drug Authorizations: 2016 Highlights. 加拿大衛生部. 14 March 2017 [7 April 2024].
^ Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC). (emc). 21 August 2019 [27 March 2020].
^ Taltz EPAR. European Medicines Agency (EMA). 2 May 2016 [27 March 2020].
^ Taltz (ixekizumab) Injection. U.S. Food and Drug Administration (FDA). 3 May 2016 [27 March 2020].
^ Vu TT, Gooderham M, Papp K. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology. November 2016, 9 (11): 1423–1433. PMID 27690669. doi:10.1080/17512433.2016.1242409.
^ Kiwalkar S, Beier S, Deodhar A. Ixekizumab for treating ankylosing spondylitis. Immunotherapy. October 2019, 11 (15): 1273–1282. PMID 31530049. doi:10.2217/imt-2019-0094.
^ ^10.0 ^10.1 ^10.2 ^10.3 ^10.4 Taltz EPAR. European Medicines Agency (EMA). 2 May 2016 [27 March 2020]. （原始內容存檔於27 March 2020）.
^ ^11.0 ^11.1 ^11.2 Ixekizumab Monograph for Professionals. Drugs.com. [26 November 2021]. （原始內容存檔於4 March 2021）（英語）.
^ Ixekizumab (Taltz) Use During Pregnancy. Drugs.com. [1 December 2021]. （原始內容存檔於27 March 2020）（英語）.

[1] 12 Difficult-to-Pronounce Drug Names. Pharmacy Times. 7 February 2018 [22 March 2018]. （原始內容存檔於21 March 2018）.

[Drugs.com_pregnancy-2] Ixekizumab (Taltz) Use During Pregnancy. Drugs.com. 27 November 2019 [27 March 2020].

[3] Prescription medicines: registration of new chemical entities in Australia, 2016. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].

[4] Health Canada New Drug Authorizations: 2016 Highlights. 加拿大衛生部. 14 March 2017 [7 April 2024].

[5] Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC). (emc). 21 August 2019 [27 March 2020].

[Taltz_EPAR-6] Taltz EPAR. European Medicines Agency (EMA). 2 May 2016 [27 March 2020].

[7] Taltz (ixekizumab) Injection. U.S. Food and Drug Administration (FDA). 3 May 2016 [27 March 2020].

[Vu2016-8] Vu TT, Gooderham M, Papp K. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology. November 2016, 9 (11): 1423–1433. PMID 27690669. doi:10.1080/17512433.2016.1242409.

[Kiwalkar2019-9] Kiwalkar S, Beier S, Deodhar A. Ixekizumab for treating ankylosing spondylitis. Immunotherapy. October 2019, 11 (15): 1273–1282. PMID 31530049. doi:10.2217/imt-2019-0094.

[EPAR2021-10] 10.0 ^10.1 ^10.2 ^10.3 ^10.4 Taltz EPAR. European Medicines Agency (EMA). 2 May 2016 [27 March 2020]. （原始內容存檔於27 March 2020）.

[AHFS2021-11] 11.0 ^11.1 ^11.2 Ixekizumab Monograph for Professionals. Drugs.com. [26 November 2021]. （原始內容存檔於4 March 2021）（英語）.

[12] Ixekizumab (Taltz) Use During Pregnancy. Drugs.com. [1 December 2021]. （原始內容存檔於27 March 2020）（英語）.

[1]

[2]

[3]

[4]

[6]

[7]

[5]

[8]

[9]

[10]

[11]

[12]